Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 3Oligodendroglioma 2Glioma 2Glioblastoma 2Brain Neoplasms 2Astrocytoma 2Advanced Malignant Solid Tumor 2Rhabdoid Tumor 1Resectable Pancreatic Cancer 1Resectable Esophageal Cancer 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Melanoma 1Medulloblastoma 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Gliosarcoma 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Adult Solid Neoplasm 1Adenoma, Islet Cell 1

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Colony-Stimulating Factors × Clear all
NCT01250470 2017-02-27

Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡